FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308207746> ?p ?o ?g. }

• W4308207746 endingPage "348" @default.
• W4308207746 startingPage "331" @default.
• W4308207746 abstract "Genetic mutations in breast cancer susceptibility gene 1 or 2 (BRCA1/2) confer a high risk for developing breast cancer; however, at least 50% of women with BRCA1/2 mutations go undiagnosed. This study evaluated differences in patient demographics, clinical characteristics, and BRCA1/2 mutation testing in the USA, European Union (EU4), and Israel in a real-world population of patients with human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC). This study was a retrospective analysis of data from the Adelphi Real World ABC Disease Specific Programme in the USA, EU4, and Israel. Medical oncologists completed a patient record form, which included detailed questions on demographics, clinical assessments and outcomes, and treatment history. Eligible patients were at least 18 years of age and receiving therapy for stage IIIb–IV ABC. Among the 2527 study patients, 407 were from the USA, 1926 were from the EU4, and 194 were from Israel; 86% had hormone receptor–positive (HR+)/HER2− ABC and 14% had triple-negative breast cancer (TNBC). Israeli patients had a higher rate of family history of BRCA-related cancer (69%) compared with patients in the EU4 (18%; p < 0.0001) and USA (18%; p < 0.0001). Among patients with HR+/HER2− ABC, the BRCA1/2 testing rate was 99% in Israel, 37% in the EU4, and 68% in the USA (p < 0.0001 vs Israel and the EU4). The age of tested patients was significantly younger in Israel (56 years) compared with the EU4 (59 years; p = 0.016 vs Israel) and USA (64 years; p < 0.0001 vs Israel and the EU4). Among patients with TNBC, the BRCA1/2 testing rate was 100% in Israel, 78% in the EU4 (p < 0.0001 vs Israel), and 93% in the USA (p < 0.002 vs the EU4). Among tested patients, genetic counseling rates were also higher in Israel (98%) compared with the EU4 (40%; p < 0.0001) and USA (38%; p < 0.0001). Testing and genetic counseling rates for BRCA1/2 mutations were very high in Israel, potentially due to the high rate of family history of BRCA-related cancer in this population and higher general awareness of genetic testing. In the EU4 and USA, overall rates of testing for BRCA1/2 mutations and genetic counseling were significantly lower compared with Israel. Given the high risk of breast cancer in BRCA1/2 mutation carriers and the efficacy of new therapies in treating ABC with a BRCA1/2 mutation, efforts should be made to improve BRCA1/2 testing rates in Europe and the USA." @default.
• W4308207746 created "2022-11-09" @default.
• W4308207746 creator A5000862048 @default.
• W4308207746 creator A5003973448 @default.
• W4308207746 creator A5031693204 @default.
• W4308207746 creator A5042633687 @default.
• W4308207746 creator A5058627245 @default.
• W4308207746 creator A5065009288 @default.
• W4308207746 creator A5075212252 @default.
• W4308207746 date "2022-10-28" @default.
• W4308207746 modified "2023-10-06" @default.
• W4308207746 title "Real-World Study of Regional Differences in Patient Demographics, Clinical Characteristics, and BRCA1/2 Mutation Testing in Patients with Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer in the United States, Europe, and Israel" @default.
• W4308207746 cites W1965557795 @default.
• W4308207746 cites W1966547535 @default.
• W4308207746 cites W1973683234 @default.
• W4308207746 cites W2011442758 @default.
• W4308207746 cites W2096382053 @default.
• W4308207746 cites W2142926844 @default.
• W4308207746 cites W2147464456 @default.
• W4308207746 cites W2298876126 @default.
• W4308207746 cites W2516150042 @default.
• W4308207746 cites W2551647681 @default.
• W4308207746 cites W2621271973 @default.
• W4308207746 cites W2761871845 @default.
• W4308207746 cites W2790993647 @default.
• W4308207746 cites W2886477543 @default.
• W4308207746 cites W2895534446 @default.
• W4308207746 cites W3118983547 @default.
• W4308207746 cites W3165576985 @default.
• W4308207746 cites W4255106880 @default.
• W4308207746 doi "https://doi.org/10.1007/s12325-022-02302-2" @default.
• W4308207746 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36333567" @default.
• W4308207746 hasPublicationYear "2022" @default.
• W4308207746 type Work @default.
• W4308207746 citedByCount "1" @default.
• W4308207746 countsByYear W43082077462023 @default.
• W4308207746 crossrefType "journal-article" @default.
• W4308207746 hasAuthorship W4308207746A5000862048 @default.
• W4308207746 hasAuthorship W4308207746A5003973448 @default.
• W4308207746 hasAuthorship W4308207746A5031693204 @default.
• W4308207746 hasAuthorship W4308207746A5042633687 @default.
• W4308207746 hasAuthorship W4308207746A5058627245 @default.
• W4308207746 hasAuthorship W4308207746A5065009288 @default.
• W4308207746 hasAuthorship W4308207746A5075212252 @default.
• W4308207746 hasBestOaLocation W43082077461 @default.
• W4308207746 hasConcept C121608353 @default.
• W4308207746 hasConcept C126322002 @default.
• W4308207746 hasConcept C143998085 @default.
• W4308207746 hasConcept C144024400 @default.
• W4308207746 hasConcept C149923435 @default.
• W4308207746 hasConcept C167135981 @default.
• W4308207746 hasConcept C195910791 @default.
• W4308207746 hasConcept C2780084366 @default.
• W4308207746 hasConcept C2780673598 @default.
• W4308207746 hasConcept C2781179581 @default.
• W4308207746 hasConcept C2908647359 @default.
• W4308207746 hasConcept C29456083 @default.
• W4308207746 hasConcept C530470458 @default.
• W4308207746 hasConcept C71924100 @default.
• W4308207746 hasConcept C99454951 @default.
• W4308207746 hasConceptScore W4308207746C121608353 @default.
• W4308207746 hasConceptScore W4308207746C126322002 @default.
• W4308207746 hasConceptScore W4308207746C143998085 @default.
• W4308207746 hasConceptScore W4308207746C144024400 @default.
• W4308207746 hasConceptScore W4308207746C149923435 @default.
• W4308207746 hasConceptScore W4308207746C167135981 @default.
• W4308207746 hasConceptScore W4308207746C195910791 @default.
• W4308207746 hasConceptScore W4308207746C2780084366 @default.
• W4308207746 hasConceptScore W4308207746C2780673598 @default.
• W4308207746 hasConceptScore W4308207746C2781179581 @default.
• W4308207746 hasConceptScore W4308207746C2908647359 @default.
• W4308207746 hasConceptScore W4308207746C29456083 @default.
• W4308207746 hasConceptScore W4308207746C530470458 @default.
• W4308207746 hasConceptScore W4308207746C71924100 @default.
• W4308207746 hasConceptScore W4308207746C99454951 @default.
• W4308207746 hasFunder F4320307765 @default.
• W4308207746 hasIssue "1" @default.
• W4308207746 hasLocation W43082077461 @default.
• W4308207746 hasLocation W43082077462 @default.
• W4308207746 hasLocation W43082077463 @default.
• W4308207746 hasOpenAccess W4308207746 @default.
• W4308207746 hasPrimaryLocation W43082077461 @default.
• W4308207746 hasRelatedWork W1996665326 @default.
• W4308207746 hasRelatedWork W2013945615 @default.
• W4308207746 hasRelatedWork W2224319365 @default.
• W4308207746 hasRelatedWork W2314332369 @default.
• W4308207746 hasRelatedWork W2408488867 @default.
• W4308207746 hasRelatedWork W2591695659 @default.
• W4308207746 hasRelatedWork W3010982918 @default.
• W4308207746 hasRelatedWork W3087947185 @default.
• W4308207746 hasRelatedWork W4293229760 @default.
• W4308207746 hasRelatedWork W4294636542 @default.
• W4308207746 hasVolume "40" @default.
• W4308207746 isParatext "false" @default.
• W4308207746 isRetracted "false" @default.
• W4308207746 workType "article" @default.